GHK-Cu vs Glow, KLOW, KPV, NAD+ and retinol: what is the difference?

What is the difference between GHK-Cu and Glow?

GHK-Cu is a single compound with a chemical identity, while Glow is a product name, and what a Glow product holds depends on its own label and paperwork. A PubMed search on 14 October 2026 for GHK-Cu together with 'glow', 'klow' or 'glow blend' returned 0 records, so that search found no published study that defines either name; it covers PubMed only. A blend holds more than one ingredient, so a result seen with a blend cannot be assigned to GHK-Cu alone. The 2018 open-label, single-arm pilot of 1,000 people used a six-part scalp formulation (five growth-factor or peptide ingredients plus copper tripeptide-1) and reported less hair fall on a pull test in 83% of patients and a higher total hair count at 1 year (P = 0.002); it had no comparison group and cannot isolate the copper tripeptide (Kapoor and Shome, Journal of Cosmetic and Laser Therapy, 2018).

The catalogue's own records for grouped products make the same point. A grouped record is a catalogue label, its contents are set with each batch, and it is not a cosmetic, skincare, medicine or supplement (catalogue product records, checked 14 October 2026). Single-compound material is listed separately, for example GHK-Cu reference material. Which ingredients a vial holds is shown by matching paperwork, and the guide to reading a certificate of analysis explains what a report can and cannot show.

What is the difference between GHK-Cu and KLOW?

KLOW, like Glow, is a product name and not a compound. A PubMed search on 14 October 2026 for GHK-Cu together with 'klow' returned 0 records, so that search found no published study that defines it. Which ingredients a KLOW product holds can be read only from that product's own label and paperwork, and two products sold under one name can differ. The practical difference from GHK-Cu is therefore not a measured effect. GHK-Cu is a named molecule with a published chemistry and research record, and a blend name is a label on a mixture whose parts must be listed to be compared.

Does any study show Glow or KLOW is better than GHK-Cu?

The sources searched for this page on 14 October 2026 did not find one. They did not find a study that ranks GHK-Cu against Glow, KLOW or any blend, so the word better has no study behind it in those sources. A fair comparison needs the same outcome measured in the same kind of people with each material, a stated recipe for each blend, and a control group. The two 2026 reviews opened for this page do not describe a study of a blend named Glow or KLOW: a systematic review of 20 GHK-Cu studies, 18 of them preclinical and 2 randomised trials, with a search to March 2026 (Mokhtar et al., Aesthetic Surgery Journal, 2026), and a systematic review (Najafi et al., Archives of Internal Medicine Research, 2026). What published studies found about GHK-Cu lists each human result with its limits.

What is the difference between GHK-Cu and KPV?

GHK-Cu and KPV are both three-amino-acid peptides, but they differ in origin and in the models where each has been studied. GHK-Cu is the copper complex of glycyl-histidyl-lysine, a peptide present in human plasma, saliva and urine (Pickart et al., BioMed Research International, 2015). KPV, lysine-proline-valine, is the C-terminal tripeptide of alpha-MSH (Brzoska et al., Endocrine Reviews, 2008). In two mouse colitis models, KPV was linked to earlier recovery, weight regain and fewer inflammatory changes, and in mice lacking a working melanocortin-1 receptor it rescued all treated animals from death during colitis, mouse results from an abstract that gives no group sizes and that do not establish a human result (Kannengiesser et al., Inflammatory Bowel Diseases, 2008). GHK-Cu has been studied mainly in wound and skin models. No study found compared them.

In the 2008 Gastroenterology study, KPV acted through PepT1, a peptide transporter, in human intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat), and reduced the incidence of two chemically induced mouse colitis models, cell-line and mouse results from an abstract that gives no group sizes and that do not establish a human result (Dalmasso et al., 2008). GHK-Cu showed mouse colitis results of its own in 2025: in mice given dextran sulfate sodium it reduced weight loss and colon shortening and lowered inflammatory cytokines, and the authors tie this to the SIRT1/STAT3 pathway, a mouse result from an abstract that gives no group sizes and that does not establish a human result (Mao et al., Frontiers in Pharmacology, 2025). Two animal results in the same organ do not make the two peptides equal. The GHK-Cu research guide covers GHK-Cu's own record.

AHK-Cu or GHK-Cu: what do the hair studies show?

The sources searched for this page on 14 October 2026 did not find a study that compared AHK-Cu with GHK-Cu for hair, so neither can be called better. AHK-Cu, copper bound to alanyl-histidyl-lysine, stimulated elongation of human hair follicles kept in culture and proliferation of cultured dermal papilla cells in a 2007 laboratory study, a culture result whose abstract gives no donor or culture counts and that does not establish a human result (Pyo et al., Archives of Pharmacal Research, 2007). The GHK-Cu hair study opened for this page is a 2026 randomised, double-blind, placebo-controlled split-face eyebrow trial in 18 adults aged 18 to 40: eyebrow hair count and diameter were higher on the GHK-Cu side than on the placebo side, mainly at week 12, and the authors report no serious adverse effects, in a small eyebrow trial that does not establish scalp-hair effects or general safety (Bo et al., *Procedia of Multidisciplinary Research*, 2026). A 2026 Pharmaceutics review describes the AHK-Cu evidence base as thin and poorly characterised (Mateescu et al., 2026).

What is the difference between GHK-Cu and NAD+?

GHK-Cu is a peptide bound to copper, while NAD+ is a coenzyme, so they are different kinds of molecule. NAD+ is a coenzyme for redox reactions, central to energy metabolism, and a cofactor for enzymes including sirtuins, CD38 and PARPs (Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021). GHK is a three-amino-acid peptide that binds copper (Pickart and Margolina, International Journal of Molecular Sciences, 2018). The question of which is better has no study behind it in the sources searched on 14 October 2026. They did not find a trial that compared the two, and each was studied for different questions. Is NAD+ a peptide? sets out why NAD+ is not.

The two meet at one enzyme in animal work. In a 2023 study of muscle, plasma GHK was lower in 9 people with COPD than in 11 age-paired healthy adults (70.27 against 133.0 ng/mL, P = 0.009), a small association that cannot establish causation (Deng et al., Journal of Cachexia, Sarcopenia and Muscle, 2023). In cultured muscle cells and cigarette-smoke-exposed mice, the same study links GHK-Cu to SIRT1, a NAD-dependent enzyme, a laboratory and animal finding whose abstract gives no culture or mouse-group counts and that does not establish a human result (Deng et al., 2023). A 2025 mouse colitis study names the SIRT1/STAT3 pathway as a target of GHK-Cu, a mouse-model finding whose abstract gives no group sizes and that does not establish a human result or equivalence with NAD+ (Mao et al., 2025). A shared pathway in mice is not evidence that the two molecules do the same thing.

What is the difference between GHK-Cu and glutathione?

Glutathione is a tripeptide of gamma-glutamyl-cysteinyl-glycine (Mazurowska and Mojski, Journal of Cosmetic Science, 2008), and GHK is a tripeptide of glycine, histidine and lysine, so both are three-amino-acid peptides with different jobs. Glutathione is the most abundant low-molecular-weight thiol made in cells and protects them from oxidative damage (Forman et al., Molecular Aspects of Medicine, 2009). GHK binds copper (Pickart and Margolina, 2018). The two meet in laboratory chemistry: in spectroscopy and voltammetry experiments, glutathione reduced copper-bound GHK through a short-lived intermediate complex, a test-tube result that does not establish a human result (Ufnalska et al., Inorganic Chemistry, 2021). No study found ranks one above the other.

Which has more evidence for ageing skin, copper peptides or retinol?

Retinol has a published randomised trial on ageing skin, and the sources searched on 14 October 2026 did not find a head-to-head trial of GHK-Cu and retinol, so studies cannot say which is better. In a randomised, double-blind, vehicle-controlled trial in 36 elderly residents (mean age 87) of 2 facilities, fine-wrinkle scores on the retinol-treated arm changed by -1.64 against -0.08 on the vehicle-treated arm after 24 weeks (P < .001; intent-to-treat with last observation carried forward), a result for retinol alone that does not compare it with GHK-Cu (Kafi et al., Archives of Dermatology, 2007). For copper peptides, a 2018 review describes a 1998 pilot comparing GHK-Cu, a vitamin C cream and retinoic acid, also called tretinoin, but the primary paper and group sizes were not verified for this page, so no comparative result is reported (Pickart and Margolina, 2018). Retinol and tretinoin are related, but they are not the same compound.

Cell work sits on the same line. In cultured skin fibroblasts, tretinoin raised bFGF, a growth factor, while copper tripeptide lowered TGF-beta1 secretion, a cell-culture result whose abstract gives no culture count and that does not establish a human result or rank materials for skin in people (McCormack et al., *Archives of Facial Plastic Surgery*, 2001).